พบ "Medical Diagnostic Equipments"ทั้งหมด 203 ผลลัพธ์
Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan. (2009)
Evidence-Based Decision-Making in Asia-Pacific with Rapidly Changing Health-Care Systems: Thailand, South Korea, and Taiwan.
Thidaporn Jirawattanapisal1 Pritaporn Kingkaew2 Tae-Jin Lee3 Ming-Chin Yang4
1International Health Policy Program, Ministry of Public Health, Muang Nonthaburi,Thailand;
2
Evidence to Inform Decision Makers in Thailand: A Cost Effectiveness Analysis of Screening and Treatment Strategies for Postmenopausal Osteoporosis. (2012)
Evidence to Inform Decision Makers in Thailand: A Cost-Effectiveness Analysis of Screening and Treatment Strategies for Postmenopausal Osteoporosis.
Pritaporn Kingkaew, BPharm, MSccorrespondenceemail, Usawadee Maleewong, BPharm, PhD, Chardpraorn Ngarmukos, MD, Yot Teerawattananon, MD, PhD
Abst
EU agency lifts lid on drug data secrets
(Reuters) – Europe’s medicines regulator, criticised in the past for excessive secrecy, is opening its data vaults to systematic scrutiny in a move that will let independent researchers trawl through millions of pages of clinical trial information.The change is a landmark in transparency that puts E
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
Abstract
BACKGROUND:
Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand- genotype 1 and 6
Abstract
BACKGROUND:
Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis C v
Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. (2013)
Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand.
Waranya Rattanavipapong1, Tanunya Koopitakkajorn1, Naiyana Praditsitthikorn1,2,*, Surakameth Mahasirimongkol3 andYot Teerawattananon1
Summary
Purpose
There is strong evidence o
Economic costs of alcohol use in Sri Lanka
Abstract
Aim
Alcohol related disease conditions are responsible for a significant proportion of morbidity and mortality in Sri Lanka. This study quantified the economic cost of selected alcohol related disease conditions in Sri Lanka in 2015.
Methods
This study uses the prevalence-based cost
Economic cost of tobacco-related cancers in Sri Lanka
Abstract
Introduction
Cancer has a high mortality rate and morbidity burden in Sri Lanka. This study estimated the economic cost of smoking and smokeless tobacco (ST) related to cancers in Sri Lanka in 2015.
Methods
Prevalence-based cost of illness is calculated according to the guidelines o
Early health technology assessment of tongue swab for non-sputum based pulmonary tuberculosis diagnosis in Thailand
Background
Sputum-based diagnostic methods for pulmonary tuberculosis (PTB) are challenging for patients who cannot produce sputum. Non-sputum-based approaches, such as tongue swab (TS), can address this gap. This study conducts an early Health Technology Assessment (HTA) of TS for PTB diagnosi
Early health technology assessment of tongue swab for non-sputum based pulmonary tuberculosis diagnosis in Thailand
Background
Sputum-based diagnostic methods for pulmonary tuberculosis (PTB) are challenging for patients who cannot produce sputum. Non-sputum-based approaches, such as tongue swab (TS), can address this gap. This study conducts an early Health Technology Assessment (HTA) of TS for PTB diagnosi
10 / หน้า